Vektor Medical

Overview

Vektor Medical is a medical technology company specializing in non-invasive, AI-based arrhythmia analysis, aimed at revolutionizing the care for conditions like atrial fibrillation. Founded in 2017 and headquartered in San Diego, Vektor Medical develops vMap®, a software technology that enhances cardiac ablation outcomes and optimizes medical procedural efficiency. The company has raised over $36 million in funding, including a recent $16 million Series A round co-led by Solas BioVentures and TVM Capital Life Science. Key figures include Rob Krummen, CEO, and Chris Villongco, CTO.

Recent Developments

May 2024: Vektor Medical showcased the comprehensive application of their vMap® technology at the Heart Rhythm 2024 conference, outlining its utility in cardiac ablation and procedural efficiency improvements.
February 2024: The company secured $16 million in Series A funding to drive the advancement and scalability of its FDA-cleared vMap platform.
January 2024: The AMA CPT Editorial Panel scheduled the implementation of a code recognizing vMap’s unique noninvasive arrhythmia analysis for July 2024.
October 2023: Vektor Medical expanded its Medical Advisory Board, including world-renowned electrophysiologists to guide its product roadmap and clinical development.
September 2023: At the HRX 2023 conference, Vektor Medical unveiled studies focusing on CT scar imaging and wall thickness analysis, highlighting the detailed arrhythmia insights vMap® provides using 12-lead ECG data.

Attribute	Information
Founding Date	2017
Headquarters	San Diego, CA
Founders	Not specifically listed, key figures include Rob Krummen, CEO
Revenue	Not publicly disclosed
Profits	Not publicly disclosed
Key Investors	Solas BioVentures, TVM Capital Life Science
Industry	Medical Technology
Number of Employees	23

Early History

Vektor Medical was founded in 2017 as a response to the unmet need for accurate and non-invasive arrhythmia mapping technology. The company's flagship product, vMap, was developed to use standard 12-lead ECG data to create a detailed mapping of the heart's arrhythmias. The breakthrough came with FDA clearance, establishing vMap as the only technology capable of performing this function non-invasively, which set the foundation for its expansion into major cardiac centers across the United States.

Company Profile and Achievements

Vektor Medical operates within the medical technology sector, with an emphasis on cardiology and arrhythmia care. Its AI-based technology, vMap, has achieved significant milestones since its inception:

2017: The company’s foundation focuses on leveraging AI for arrhythmia solutions.
2019: vMap receives FDA clearance, becoming a pioneer in the field with its non-invasive capabilities.
2022: Expansion of vMap utilization to several leading cardiac centers across the United States.
2023-2024: Recent funding rounds and advisory board expansion underscore the growing trust in Vektor Medical's technology and strategic direction.

Current Operations and Market Position

Currently, Vektor Medical remains at the forefront of arrhythmia care innovation, utilizing vMap technology to improve clinical outcomes and operational efficiency across healthcare facilities. It aims to expand vMap's deployment across dozens of hospitals by end of 2024, reinforcing its market position as a leader in non-invasive cardiac mapping.

Conclusion

Vektor Medical has carved a significant niche in the medical technology landscape through its innovative use of AI in arrhythmia care. With its continued research, funding, and strategic partnerships, the company is well-positioned to transform cardiac ablation procedures and overall patient outcomes, maintaining a trajectory of growth and expansion in the medical sector.